CR20170187A - 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer - Google Patents
2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de AlzheimerInfo
- Publication number
- CR20170187A CR20170187A CR20170187A CR20170187A CR20170187A CR 20170187 A CR20170187 A CR 20170187A CR 20170187 A CR20170187 A CR 20170187A CR 20170187 A CR20170187 A CR 20170187A CR 20170187 A CR20170187 A CR 20170187A
- Authority
- CR
- Costa Rica
- Prior art keywords
- alzheimer
- disease
- tetrahydropyridines
- difluoro
- phenyl
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- OTXMPMLVLBGHJE-UHFFFAOYSA-N CC(C(CC1F)F)(C2=CC=CC=C2)N=C1N Chemical class CC(C(CC1F)F)(C2=CC=CC=C2)N=C1N OTXMPMLVLBGHJE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se dirige a compuestos de acuerdo con la Fórmula I, compuestos que son inhibidores de la enzima BACE1. Aspectos separados de la invención se dirigen a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos para los cuales la reducción de depósitos de Aß es beneficiosa tal como la enfermedad de Alzheimer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400649 | 2014-11-10 | ||
| DKPA201500450 | 2015-08-07 | ||
| PCT/EP2015/076014 WO2016075062A1 (en) | 2014-11-10 | 2015-11-09 | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170187A true CR20170187A (es) | 2018-02-01 |
Family
ID=54476983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170187A CR20170187A (es) | 2014-11-10 | 2014-11-09 | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10059669B2 (es) |
| EP (1) | EP3218362B1 (es) |
| JP (1) | JP2017533253A (es) |
| KR (1) | KR20170082529A (es) |
| CN (1) | CN107074809A (es) |
| AU (1) | AU2015345257A1 (es) |
| BR (1) | BR112017009647A2 (es) |
| CA (1) | CA2964305A1 (es) |
| CL (1) | CL2017001113A1 (es) |
| CO (1) | CO2017004530A2 (es) |
| CR (1) | CR20170187A (es) |
| DO (1) | DOP2017000118A (es) |
| EA (1) | EA201790817A1 (es) |
| EC (1) | ECSP17028463A (es) |
| ES (1) | ES2710602T3 (es) |
| IL (1) | IL252091A0 (es) |
| MX (1) | MX2017006048A (es) |
| NI (1) | NI201700056A (es) |
| PE (1) | PE20170947A1 (es) |
| PH (1) | PH12017500829A1 (es) |
| RU (1) | RU2017116197A (es) |
| SG (1) | SG11201703177WA (es) |
| SV (1) | SV2017005434A (es) |
| TN (1) | TN2017000134A1 (es) |
| WO (1) | WO2016075062A1 (es) |
| ZA (1) | ZA201702799B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| RU2018104868A (ru) | 2015-08-12 | 2019-09-13 | Х. Лундбекк А/С | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| CN106366073B (zh) * | 2016-10-24 | 2018-11-30 | 扬子江药业集团南京海陵药业有限公司 | 一种盐酸替吡嘧啶的制备方法 |
| LT3532064T (lt) | 2016-10-28 | 2020-09-25 | H. Lundbeck A/S | Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui |
| RU2019108717A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов |
| BR112018017058A2 (pt) * | 2016-12-21 | 2019-07-02 | H Lundbeck As | 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetra-hidropiridin-2-il-fenil-5-(metóxi-d3)-pirazina-2-carboxamidas e derivados fluorados do mesmo como inibidores de bace1 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| RU2020118913A (ru) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| CN109970681A (zh) * | 2019-04-19 | 2019-07-05 | 安徽海康药业有限责任公司 | 一种瑞格列奈的合成方法 |
| CN113720930A (zh) * | 2021-07-26 | 2021-11-30 | 南京一诺医药科技有限公司 | 一种hplc-ms/ms联用检测人血浆中奥美拉唑的方法 |
| CN114235985A (zh) * | 2021-11-25 | 2022-03-25 | 南京海纳医药科技股份有限公司 | 一种hplc-ms/ms联用检测人血浆中胍法辛的方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395257A1 (en) | 2001-06-12 | 2004-03-10 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| CN100369898C (zh) | 2002-02-12 | 2008-02-20 | 史密丝克莱恩比彻姆公司 | 用作p38抑制剂的烟酰胺衍生物 |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| AR081587A1 (es) * | 2010-06-09 | 2012-10-03 | Janssen Pharmaceutica Nv | DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE) |
| CN103429589A (zh) | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
| KR101569260B1 (ko) | 2011-01-13 | 2015-11-13 | 노파르티스 아게 | 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도 |
| US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| AU2012266544A1 (en) | 2011-06-07 | 2013-11-21 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| US9493485B2 (en) | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
| WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
| WO2014059185A1 (en) * | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Ｂａｃｅ抑制劑 |
| US20170066741A1 (en) | 2014-02-19 | 2017-03-09 | H. Lundbeck A/S | 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| RU2018104868A (ru) | 2015-08-12 | 2019-09-13 | Х. Лундбекк А/С | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 |
-
2014
- 2014-11-09 CR CR20170187A patent/CR20170187A/es unknown
-
2015
- 2015-11-09 JP JP2017525124A patent/JP2017533253A/ja active Pending
- 2015-11-09 AU AU2015345257A patent/AU2015345257A1/en not_active Abandoned
- 2015-11-09 TN TN2017000134A patent/TN2017000134A1/en unknown
- 2015-11-09 CN CN201580060814.7A patent/CN107074809A/zh active Pending
- 2015-11-09 RU RU2017116197A patent/RU2017116197A/ru unknown
- 2015-11-09 EP EP15790975.5A patent/EP3218362B1/en active Active
- 2015-11-09 SG SG11201703177WA patent/SG11201703177WA/en unknown
- 2015-11-09 EA EA201790817A patent/EA201790817A1/ru unknown
- 2015-11-09 PE PE2017000827A patent/PE20170947A1/es unknown
- 2015-11-09 BR BR112017009647A patent/BR112017009647A2/pt not_active Application Discontinuation
- 2015-11-09 US US15/524,479 patent/US10059669B2/en not_active Expired - Fee Related
- 2015-11-09 ES ES15790975T patent/ES2710602T3/es active Active
- 2015-11-09 MX MX2017006048A patent/MX2017006048A/es unknown
- 2015-11-09 CA CA2964305A patent/CA2964305A1/en not_active Abandoned
- 2015-11-09 WO PCT/EP2015/076014 patent/WO2016075062A1/en not_active Ceased
- 2015-11-09 KR KR1020177012461A patent/KR20170082529A/ko not_active Withdrawn
-
2017
- 2017-04-20 ZA ZA2017/02799A patent/ZA201702799B/en unknown
- 2017-05-03 IL IL252091A patent/IL252091A0/en unknown
- 2017-05-04 PH PH12017500829A patent/PH12017500829A1/en unknown
- 2017-05-04 CL CL2017001113A patent/CL2017001113A1/es unknown
- 2017-05-05 CO CONC2017/0004530A patent/CO2017004530A2/es unknown
- 2017-05-09 DO DO2017000118A patent/DOP2017000118A/es unknown
- 2017-05-09 EC ECIEPI201728463A patent/ECSP17028463A/es unknown
- 2017-05-09 SV SV2017005434A patent/SV2017005434A/es unknown
- 2017-05-10 NI NI201700056A patent/NI201700056A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016075062A1 (en) | 2016-05-19 |
| CN107074809A (zh) | 2017-08-18 |
| AU2015345257A1 (en) | 2017-05-04 |
| MX2017006048A (es) | 2017-06-19 |
| NI201700056A (es) | 2017-09-22 |
| KR20170082529A (ko) | 2017-07-14 |
| PH12017500829A1 (en) | 2017-10-09 |
| EP3218362A1 (en) | 2017-09-20 |
| ZA201702799B (en) | 2018-08-29 |
| CO2017004530A2 (es) | 2017-07-28 |
| SG11201703177WA (en) | 2017-05-30 |
| US10059669B2 (en) | 2018-08-28 |
| JP2017533253A (ja) | 2017-11-09 |
| CL2017001113A1 (es) | 2017-12-01 |
| EA201790817A1 (ru) | 2017-09-29 |
| ECSP17028463A (es) | 2017-08-31 |
| SV2017005434A (es) | 2017-07-19 |
| US20170313658A1 (en) | 2017-11-02 |
| CA2964305A1 (en) | 2016-05-19 |
| DOP2017000118A (es) | 2017-07-15 |
| IL252091A0 (en) | 2017-07-31 |
| TN2017000134A1 (en) | 2018-10-19 |
| BR112017009647A2 (pt) | 2017-12-19 |
| RU2017116197A (ru) | 2018-12-13 |
| PE20170947A1 (es) | 2017-07-13 |
| ES2710602T3 (es) | 2019-04-26 |
| EP3218362B1 (en) | 2019-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000118A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| ECSP17028459A (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CO2017005588A2 (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| MX388562B (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| EA201791804A1 (ru) | Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс | |
| MX2017001603A (es) | Derivados de piperazina como moduladores de los receptores x del higado. | |
| BR112018070255A2 (pt) | reprogramação cardíaca direta melhorada. | |
| UY36081A (es) | Compuestos inhibidores de metaloenzima como fungicidas. | |
| MX2019000982A (es) | Compuestos y composiciones y usos de los mismos. | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| CL2017002229A1 (es) | Inhibidores de bace1. |